GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ThermoGenesis Holdings Inc (STU:THR) » Definitions » Price-to-Owner-Earnings

ThermoGenesis Holdings (STU:THR) Price-to-Owner-Earnings : (As of May. 24, 2024)


View and export this data going back to . Start your Free Trial

What is ThermoGenesis Holdings Price-to-Owner-Earnings?

As of today (2024-05-24), ThermoGenesis Holdings's share price is €0.482. ThermoGenesis Holdings does not have enough data to calculate Owner Earnings per Share (TTM), so as pPrice-to-Owner-Earnings.


The historical rank and industry rank for ThermoGenesis Holdings's Price-to-Owner-Earnings or its related term are showing as below:


STU:THR's Price-to-Owner-Earnings is not ranked *
in the Medical Devices & Instruments industry.
Industry Median: 33.29
* Ranked among companies with meaningful Price-to-Owner-Earnings only.

As of today (2024-05-24), ThermoGenesis Holdings's share price is €0.482. ThermoGenesis Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was €-4.75. Therefore, ThermoGenesis Holdings's PE Ratio for today is At Loss.

As of today (2024-05-24), ThermoGenesis Holdings's share price is €0.482. ThermoGenesis Holdings's EPS without NRI for the trailing twelve months (TTM) ended in was €-4.20. Therefore, ThermoGenesis Holdings's PE Ratio without NRI for today is At Loss.


ThermoGenesis Holdings Price-to-Owner-Earnings Historical Data

The historical data trend for ThermoGenesis Holdings's Price-to-Owner-Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ThermoGenesis Holdings Price-to-Owner-Earnings Chart

ThermoGenesis Holdings Annual Data
Trend Jun14 Jun15 Jun16 Jun17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Price-to-Owner-Earnings
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

ThermoGenesis Holdings Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Price-to-Owner-Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of ThermoGenesis Holdings's Price-to-Owner-Earnings

For the Medical Devices subindustry, ThermoGenesis Holdings's Price-to-Owner-Earnings, along with its competitors' market caps and Price-to-Owner-Earnings data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ThermoGenesis Holdings's Price-to-Owner-Earnings Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, ThermoGenesis Holdings's Price-to-Owner-Earnings distribution charts can be found below:

* The bar in red indicates where ThermoGenesis Holdings's Price-to-Owner-Earnings falls into.



ThermoGenesis Holdings Price-to-Owner-Earnings Calculation

In 1986 Berkshire Hathaway Shareholder Letter, Warren Buffett defined owner earnings as follows:

"These represent (a) reported earnings plus (b) depreciation, depletion, amortization, and certain other non-cash charges...less (c) the average annual amount of capitalized expenditures for plant and equipment, etc. that the business requires to fully maintain its long-term competitive position and its unit volume. (If the business requires additional working capital to maintain its competitive position and unit volume, the increment also should be included in (c))...Our owner-earnings equation does not yield the deceptively precise figures provided by GAAP, since (c) must be a guess - and one sometimes very difficult to make. Despite this problem, we consider the owner earnings figure, not the GAAP figure, to be the relevant item for valuation purposes - both for investors in buying stocks and for managers in buying entire businesses...All of this points up the absurdity of the 'cash flow' numbers that are often set forth in Wall Street reports. These numbers routinely include (a) plus (b) - but do not subtract (c)."

ThermoGenesis Holdings's Price-to-Owner-Earnings for today is calculated as

Price-to-Owner-Earnings=Share Price/Owner Earnings per Share (TTM)
=0.482/-2.31
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


ThermoGenesis Holdings  (STU:THR) Price-to-Owner-Earnings Explanation

For how to get Owner Earnings per Share (TTM), please click.


ThermoGenesis Holdings Price-to-Owner-Earnings Related Terms

Thank you for viewing the detailed overview of ThermoGenesis Holdings's Price-to-Owner-Earnings provided by GuruFocus.com. Please click on the following links to see related term pages.


ThermoGenesis Holdings (STU:THR) Business Description

Traded in Other Exchanges
Address
2711 Citrus Road, Rancho Cordova, CA, USA, 95742
ThermoGenesis Holdings Inc develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. The company currently markets a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology, including its semi-automated, functionally-closed CAR-TXpress platform, which streamlines the manufacturing process for the emerging CAR-T immunotherapy market. It offers the AutoXpress and BioArchive platforms for automated clinical bio-banking, PXP platform for point-of-care cell-based therapies and CAR-TXpress platform for bio-manufacturing for immuno-oncology applications.